FMP
Avidity Biosciences, Inc.
RNA
NASDAQ
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
31.82 USD
0.77 (2.42%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Ms. Sarah Boyce
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
CIK
0001599901
ISIN
US05370A1088
CUSIP
05370A108
Address
10578 Science Center Drive
Phone
858 401 7900
Country
US
Employee
253
IPO Date
Jun 12, 2020
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
RNA Financial Summary
CIK
0001599901
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
05370A108
ISIN
US05370A1088
Country
US
Price
31.82
Beta
0.91
Volume Avg.
1.16M
Market Cap
3.8B
Shares
-
52-Week
8.86-56.0
DCF
-4.02
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-11.05
P/B
-
Website
https://www.aviditybiosciences.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest RNA News
It looks like there's no news available.
